{"id":14335,"date":"2020-08-24T11:36:56","date_gmt":"2020-08-24T09:36:56","guid":{"rendered":"https:\/\/idibell.cat\/es\/?p=14335"},"modified":"2020-09-01T10:46:51","modified_gmt":"2020-09-01T08:46:51","slug":"identifican-una-nueva-combinacion-de-farmacos-para-tratar-rabdomiosarcoma-un-tumor-altamente-agresivo-en-ninos","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2020\/08\/identifican-una-nueva-combinacion-de-farmacos-para-tratar-rabdomiosarcoma-un-tumor-altamente-agresivo-en-ninos\/","title":{"rendered":"Identifican una nueva combinaci\u00f3n de f\u00e1rmacos para tratar rabdomiosarcoma, un tumor altamente agresivo en ni\u00f1os"},"content":{"rendered":"

El grupo de quimiorresistencia<\/a> del Programa ProCURE del IDIBELL e ICO, bajo la direcci\u00f3n del Dr Alberto Villanueva<\/strong>, ha colaborado en un estudio liderado por el Instituto de Bioingenier\u00eda de Catalu\u00f1a (IBEC<\/a>) en el que han investigado el uso secuencial de combinaciones de dosis bajas de agentes quimioterap\u00e9uticos con mim\u00e9ticos BH3 para aumentar la eficacia de los tratamientos actuales del rabdomiosarcoma, un tumor pedi\u00e1trico muy agresivo. Esta nueva estrategia, a la vez que mejora la respuesta antitumoral, disminuye la toxicidad inducida por la terapia y la protecci\u00f3n antiapopt\u00f3tica evitando la resistencia a los tratamientos. En la investigaci\u00f3n, se han combinado tanto estudios in vitro en l\u00edneas celulares como in vivo en orthoxenografts, o PDOX derivados de pacientes.<\/p>\n

El equipo de Alberto Villanueva ha trasladado su amplia experiencia en la generaci\u00f3n de modelos tumorales ortot\u00f3picos en ratones, es decir, fragmentos de tumores humanos implantados en los ratones en el mismo \u00f3rgano de origen, de tumores de adultos al terreno pedi\u00e1trico con el objetivo de ayudar a mejorar su tratamiento. As\u00ed, en los \u00faltimos a\u00f1os y en colaboraci\u00f3n, en su mayor\u00eda, con el Servicio de Oncolog\u00eda Pedi\u00e1trica del Hospital Vall d’Hebron han generado un importante banco de este tipo de modelos tumorales pedi\u00e1tricos. Uno de ellos es el que se ha utilizado para poder avanzar en la mejora del tratamiento del rabdomiosarcoma presentado en este trabajo. Asimismo, en este estudio adem\u00e1s tambi\u00e9n ha participado la unidad de Oncol\u00f3gica Pedi\u00e1trica del Hospital de Sant Joan de Deu, as\u00ed como el spin-off Xenopat S.L como parte de su acci\u00f3n social corporativa.<\/p>\n

El rabdomiosarcoma, el sarcoma de tejidos blandos m\u00e1s frecuente en pacientes pedi\u00e1tricos, es un tipo de tumor altamente agresivo y que no suele tener buen pron\u00f3stico, especialmente en pacientes refractarios o con reca\u00edda. Actualmente la estrategia terap\u00e9utica incluye quimioterapia, radioterapia y cirug\u00eda pero la baja tasa de supervivencia en pacientes de alto riesgo, as\u00ed como las elevadas toxicidades derivadas del tratamiento y la falta de biomarcadores evidencian la necesidad de nuevas estrategias terap\u00e9uticas.<\/p>\n","protected":false},"excerpt":{"rendered":"

El grupo de quimiorresistencia del Programa ProCURE del IDIBELL e ICO, liderado por Alberto Villanueva, ha trasladado su experiencia en la generaci\u00f3n de modelos ortot\u00f3picos de ratones en pacientes adultos al terreno pedi\u00e1trico.<\/p>\n","protected":false},"author":8,"featured_media":14336,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[206],"tags":[],"class_list":["post-14335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-quimioresistencia-tumoral-y-estromal"],"publishpress_future_action":{"enabled":false,"date":"2024-12-25 18:23:41","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/14335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=14335"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/14335\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/14336"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=14335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=14335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=14335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}